A New Way to Measure Prodromal Synucleinopathy: What the PSRS Adds for RBD Clinical Trials
The PSRS showed good-to-excellent reliability and moderate-to-strong construct validity in a large RBD cohort, supporting its use as a multidomain measure of prodromal synucleinopathy burden.